131 related articles for article (PubMed ID: 35772003)
61. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study.
Shen KN; Zhang CL; Tian Z; Feng J; Wang YN; Sun J; Zhang L; Cao XX; Zhou DB; Li J
Amyloid; 2019 Jun; 26(2):66-73. PubMed ID: 31074308
[No Abstract] [Full Text] [Related]
62. Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis.
Muchtar E; Magen H; Itchaki G; Cohen A; Rosenfeld R; Shochat T; Kornowski R; Iakobishvili Z; Raanani P
Leuk Res; 2016 Feb; 41():56-61. PubMed ID: 26658109
[TBL] [Abstract][Full Text] [Related]
63. Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T; Gatt M; Lavie N; Vaxman I; Tadmor T; Rouvio O; Zektser M; Horowitz N; Magen H; Ballan M; Suru C; Luttwak E; Levi S; Ziv-Baran T; Avivi I; Cohen YC
Eur J Haematol; 2021 Feb; 106(2):184-195. PubMed ID: 33090552
[TBL] [Abstract][Full Text] [Related]
64. Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
Madan S; Dispenzieri A; Lacy MQ; Buadi F; Hayman SR; Zeldenrust SR; Rajkumar SV; Gertz MA; Kumar SK
Mayo Clin Proc; 2010 Mar; 85(3):232-8. PubMed ID: 20194151
[TBL] [Abstract][Full Text] [Related]
65. Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.
Caccialanza R; Palladini G; Klersy C; Cereda E; Bonardi C; Cameletti B; Quarleri L; Montagna E; Foli A; Milani P; Lavatelli F; Marena C; Merlini G
JPEN J Parenter Enteral Nutr; 2014 Sep; 38(7):891-4. PubMed ID: 24072737
[TBL] [Abstract][Full Text] [Related]
66. Clinical Analysis of Cardiac Involvement in 53 Patients With Multiple Myeloma Coexistent With Light Chain Amyloidosis.
Yu Y; Huang Z; Hu W; Li X; Shen M; Zhang J; Tang R; Chen S; Chen W
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):519-525.e1. PubMed ID: 32389672
[TBL] [Abstract][Full Text] [Related]
67. [Attainment of complete hematological remission is crucial for extended survival of AL amyloidosis patients with cardiac involvement].
Pika T; Lochman P; Vymětal J; Metelka R; Minařík J; Látalová P; Zapletalová J; Bačovský J; Ščudla V
Klin Onkol; 2013; 26(5):343-7. PubMed ID: 24107157
[TBL] [Abstract][Full Text] [Related]
68. Autologous stem cell transplantation for AL amyloidosis: adjustment of melphalan dose by factors including BNP.
Hayashi T; Ikeda H; Igarashi T; Maruyama Y; Aoki Y; Nojima M; Ishida T; Shinomura Y
Int J Hematol; 2014 Dec; 100(6):554-8. PubMed ID: 25281404
[TBL] [Abstract][Full Text] [Related]
69. Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light-chain amyloidosis.
Cohen OC; Sharpley F; Gillmore JD; Lachmann HJ; Sachchithanantham S; Mahmood S; Fontana M; Whelan CJ; Martinez-Naharro A; Kyriakou C; Rabin N; Popat R; Yong K; Cheesman S; Shah R; Hawkins PN; Wechalekar AD
Br J Haematol; 2020 May; 189(4):643-649. PubMed ID: 31984481
[TBL] [Abstract][Full Text] [Related]
70. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
71. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
Wechalekar AD; Schonland SO; Kastritis E; Gillmore JD; Dimopoulos MA; Lane T; Foli A; Foard D; Milani P; Rannigan L; Hegenbart U; Hawkins PN; Merlini G; Palladini G
Blood; 2013 Apr; 121(17):3420-7. PubMed ID: 23479568
[TBL] [Abstract][Full Text] [Related]
72. Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.
Li X; Huang B; Liu J; Chen M; Gu J; Li J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):913-919. PubMed ID: 33966111
[TBL] [Abstract][Full Text] [Related]
73. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Leukemia; 2018 Mar; 32(3):729-735. PubMed ID: 28919633
[TBL] [Abstract][Full Text] [Related]
74. Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Tovar N; Rodríguez-Lobato LG; Cibeira MT; Magnano L; Isola I; Rosiñol L; Bladé J; Fernández de Larrea C
Amyloid; 2018 Jun; 25(2):79-85. PubMed ID: 29482381
[TBL] [Abstract][Full Text] [Related]
75. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schönland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim JS; Crusoe E; Ahmadi T; Tran N; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL;
N Engl J Med; 2021 Jul; 385(1):46-58. PubMed ID: 34192431
[TBL] [Abstract][Full Text] [Related]
76. Prognostic Factors of AL-PCMM and AL-MM: A Single-Center Retrospective Study.
Xu J; Qiu Z; Yan M; Wang B; Song Z; Liu H; Wang M; Cen X
Int J Med Sci; 2022; 19(3):588-595. PubMed ID: 35370457
[No Abstract] [Full Text] [Related]
77. A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
Ravichandran S; Mahmood S; Wisniowski B; Sachchithanantham S; Popat R; Lachmann H; Rabin N; Ramasamy K; Hawkins S; Kyriakou C; Gillmore J; Yong K; Hawkins P; Jackson G; Pratt G; D Wechalekar A
Br J Haematol; 2022 Jul; 198(2):328-332. PubMed ID: 35509237
[TBL] [Abstract][Full Text] [Related]
78. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
79. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.
Jeryczynski G; Antlanger M; Duca F; Binder-Rodriguez C; Reiter T; Simonitsch-Klupp I; Bonderman D; Kain R; Krauth MT; Agis H
ESMO Open; 2021 Apr; 6(2):100065. PubMed ID: 33667762
[TBL] [Abstract][Full Text] [Related]
80. AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome.
Wechalekar AD; Lachmann HJ; Goodman HJ; Bradwell A; Hawkins PN; Gillmore JD
Blood; 2008 Nov; 112(10):4009-16. PubMed ID: 18708629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]